| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0140-6736(10)61030-6 |
| P698 | PubMed publication ID | 20728932 |
| P50 | author | Jun Zhang | Q56256577 |
| P2093 | author name string | Hua Wang | |
| Xin Yao | |||
| Qiang Yan | |||
| Ting Wu | |||
| Xue-Feng Zhang | |||
| Yi-Jun Wang | |||
| Cheng Zhou | |||
| Feng-Cai Zhu | |||
| Yue-Mei Hu | |||
| Ning-Shao Xia | |||
| Xing Ai | |||
| Ji Miao | |||
| Chang-Lin Yang | |||
| Han-Min Jiang | |||
| Shou-Jie Huang | |||
| Zhong-Ze Wang | |||
| Quan Tang | |||
| Yi-Min Li | |||
| James Wai-Kuo Shih | |||
| Mun-Hon Ng | |||
| Yang-Ling Xian | |||
| Jia-Ping Cai | |||
| P2860 | cites work | Hepatitis E epidemic, Uganda | Q24609019 |
| Comparison of a new immunochromatographic test to enzyme-linked immunosorbent assay for rapid detection of immunoglobulin m antibodies to hepatitis e virus in human sera | Q33788603 | ||
| Hepatitis E outbreak on cruise ship. | Q33800746 | ||
| Hepatitis E: an emerging infectious disease | Q33842661 | ||
| Safety and efficacy of a recombinant hepatitis E vaccine | Q34002701 | ||
| Hepatitis E vaccines: progress and prospects | Q35826279 | ||
| Seroprevalence of hepatitis E virus infection, rural southern People's Republic of China | Q36023562 | ||
| Phylogenetic analysis of global hepatitis E virus sequences: genetic diversity, subtypes and zoonosis | Q36263223 | ||
| Hepatitis E: an emerging awareness of an old disease | Q37055890 | ||
| Hepatitis E: a curious zoonosis | Q37175852 | ||
| Hepatitis E: an emerging infection in developed countries. | Q37320904 | ||
| Hepatitis A and E: update on prevention and epidemiology | Q42640194 | ||
| Hepatitis E virus superinfection in patients with chronic liver disease | Q44320311 | ||
| Persistent carriage of hepatitis E virus in patients with HIV infection. | Q45019291 | ||
| Serological response to hepatitis E virus genotype 3 infection: IgG quantitation, avidity, and IgM response. | Q45398995 | ||
| Hepatitis E virus (HEV) infection in patients with cirrhosis is associated with rapid decompensation and death | Q45409801 | ||
| Evaluation of antibody-based and nucleic acid-based assays for diagnosis of hepatitis E virus infection in a rhesus monkey model. | Q45710834 | ||
| A bacterially expressed particulate hepatitis E vaccine: antigenicity, immunogenicity and protectivity on primates. | Q51525883 | ||
| Hepatitis E virus. | Q53862581 | ||
| Aetiology, clinical course and outcome of sporadic acute viral hepatitis in pregnancy* | Q59829993 | ||
| Incidence and severity of viral hepatitis in pregnancy | Q59830166 | ||
| Locally acquired hepatitis E in chronic liver disease | Q80158899 | ||
| Randomized-controlled phase II clinical trial of a bacterially expressed recombinant hepatitis E vaccine | Q83235565 | ||
| P433 | issue | 9744 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | vaccine | Q134808 |
| placebo | Q269829 | ||
| hepatitis E | Q326643 | ||
| phase III clinical trial | Q42824827 | ||
| P304 | page(s) | 895-902 | |
| P577 | publication date | 2010-08-20 | |
| P1433 | published in | The Lancet | Q939416 |
| P1476 | title | Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial | |
| P478 | volume | 376 |
| Q30375781 | A Comprehensive Study of Neutralizing Antigenic Sites on the Hepatitis E Virus (HEV) Capsid by Constructing, Clustering, and Characterizing a Tool Box. |
| Q40038985 | A Recombinant HAV Expressing a Neutralization Epitope of HEV Induces Immune Response against HAV and HEV in Mice |
| Q36845713 | A high-throughput neutralizing assay for antibodies and sera against hepatitis E virus |
| Q41178447 | A novel linear neutralizing epitope of hepatitis E virus |
| Q40084653 | A phase 1 randomized open-label clinical study to evaluate the safety and tolerability of a novel recombinant hepatitis E vaccine |
| Q37197088 | A preliminary cost-effectiveness analysis of hepatitis E vaccination among pregnant women in epidemic regions |
| Q40585281 | A shared N-terminal hydrophobic tail for the formation of nanoparticulates |
| Q38213327 | A systematic review of hepatitis E virus infection in children |
| Q33747037 | A systematic review of the epidemiology of hepatitis E virus in Africa |
| Q35331616 | A valuable antigen detection method for diagnosis of acute hepatitis E. |
| Q38182586 | Absence of chronic hepatitis E in a German cohort of common variable immunodeficiency patients |
| Q28069291 | Acute Hepatitis E: Two Sides of the Same Coin |
| Q36845686 | Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury |
| Q28077096 | Adult immunization-Need of the hour |
| Q30251421 | Advances in hepatitis E - II: Epidemiology, clinical manifestations, treatment and prevention. |
| Q61817654 | An Optimized High-Throughput Neutralization Assay for Hepatitis E Virus (HEV) Involving Detection of Secreted Porf2 |
| Q45323681 | An ethanol extract of Lysimachia mauritiana exhibits inhibitory activity against hepatitis E virus genotype 3 replication |
| Q34722613 | An exploratory case control study of risk factors for hepatitis E in rural Bangladesh. |
| Q45324688 | An overview: Rabbit hepatitis E virus (HEV) and rabbit providing an animal model for HEV study |
| Q38073654 | An update on the hepatitis E virus. |
| Q40507421 | Animal Models for Hepatitis E Virus |
| Q92879574 | Animal Models for Hepatitis E virus |
| Q36973372 | Antigenic determinants of hepatitis E virus and vaccine-induced immunogenicity and efficacy. |
| Q38174398 | Antiviral strategies for hepatitis E virus |
| Q36245120 | Assessment of the cross-protective capability of recombinant capsid proteins derived from pig, rat, and avian hepatitis E viruses (HEV) against challenge with a genotype 3 HEV in pigs |
| Q26996093 | Autochthonous Hepatitis E Virus Infection in Europe: A Matter of Concern for Public Health? |
| Q37630325 | Autochthonous hepatitis e virus infections: a new transfusion-associated risk? |
| Q42222473 | Bacteria expressed hepatitis E virus capsid proteins maintain virion-like epitopes |
| Q28728496 | Bats worldwide carry hepatitis E virus-related viruses that form a putative novel genus within the family Hepeviridae |
| Q38172045 | Bioengineering virus-like particles as vaccines |
| Q34064413 | Branched-linear and agglomerate protein polymers as vaccine platforms |
| Q38385396 | Broad spectrum assessment of the epitope fluctuation--Immunogenicity hypothesis. |
| Q30251843 | Case-fatality risk of pregnant women with acute viral hepatitis type E: a systematic review and meta-analysis |
| Q36171812 | Characterization of hepatitis E virus recombinant ORF2 proteins expressed by vaccinia viruses |
| Q38854773 | Characterization of self-assembled virus-like particles of dromedary camel hepatitis e virus generated by recombinant baculoviruses |
| Q40055037 | Characterization of the Quasi-Enveloped Hepatitis E Virus Particles Released by the Cellular Exosomal Pathway |
| Q36134262 | Characterization of the Specificity, Functionality, and Durability of Host T-Cell Responses Against the Full-Length Hepatitis E Virus |
| Q38832137 | Characterizing Enterovirus 71 and Coxsackievirus A16 virus-like particles production in insect cells. |
| Q38362086 | Chinese vaccine products go global: vaccine development and quality control |
| Q87196414 | Chronic hepatitis E in an immunocompetent patient: a case report |
| Q59240797 | Chronic hepatitis E in hematopoietic stem cell transplant patients in a low-endemic country? |
| Q26784271 | Chronic hepatitis E: A brief review |
| Q43443385 | Chronic hepatitis e in heart transplant recipients |
| Q36417563 | Chronic hepatitis e infection resulting in graft failure in a liver transplant tourist |
| Q43168143 | Classification of human and zoonotic group hepatitis E virus (HEV) using antigen detection |
| Q93002309 | Clinical Manifestations, Pathogenesis and Treatment of Hepatitis E Virus Infections |
| Q91941584 | Clinical presentations of Hepatitis E: A clinical review with representative case histories |
| Q34437470 | Codon-Optimized Expression and Purification of Truncated ORF2 Protein of Hepatitis E Virus in Escherichia coli |
| Q33577945 | Commercializing diarrhea vaccines for travelers. |
| Q35887653 | Comparable quality attributes of hepatitis E vaccine antigen with and without adjuvant adsorption-dissolution treatment |
| Q42242623 | Course and treatment of chronic hepatitis E virus infection in lung transplant recipients |
| Q39024688 | Cross-genotype-specific T-cell responses in acute hepatitis E virus (HEV) infection. |
| Q26782030 | Current Knowledge on Hepatitis E |
| Q36318218 | Cynomolgus monkeys are successfully and persistently infected with hepatitis E virus genotype 3 (HEV-3) after long-term immunosuppressive therapy |
| Q36103394 | Cytokine Profiles and Cell Proliferation Responses to Truncated ORF2 Protein in Iranian Patients Recovered from Hepatitis E Infection |
| Q39027960 | Design and production of a multiepitope construct derived from hepatitis E virus capsid protein |
| Q35189231 | Detection of serum antibodies to hepatitis E virus in domestic pigs in Italy using a recombinant swine HEV capsid protein |
| Q38100039 | Developing Countries Vaccine Manufacturers Network: doing good by making high-quality vaccines affordable for all. |
| Q42004604 | Development of a vectored vaccine against hepatitis E virus |
| Q37628823 | Development of enzyme-linked immunosorbent assays using 2 truncated ORF2 proteins for detection of IgG antibodies against hepatitis E virus |
| Q56588500 | Development of new hepatitis E vaccines |
| Q34164503 | Discovery of hepatitis E: the epidemic non-A, non-B hepatitis 30 years down the memory lane. |
| Q39094061 | Disease burden of hepatitis E in a rural population in China: a community-based survey |
| Q40302625 | Dynamics of 8G12 competitive antibody in "prime-boost" vaccination of Hepatitis E vaccine |
| Q33561240 | EV71 vaccines: a milestone in the history of global vaccine development |
| Q42616164 | Effector T cells immune reactivity among patients with acute hepatitis E. |
| Q64124343 | Efficacy, safety, and immunogenicity of an Escherichia coli-produced bivalent human papillomavirus vaccine: An interim analysis of a randomized clinical trial |
| Q35683323 | Enhanced humoral response in pregnant mice immunized with liposome encapsulated recombinant neutralizing epitope protein of Hepatitis- E virus |
| Q35391544 | Enhanced mucosal immune responses induced by a combined candidate mucosal vaccine based on Hepatitis A virus and Hepatitis E virus structural proteins linked to tuftsin |
| Q38966704 | Epidemiology of HEV infection during pregnancy in Benin |
| Q28072683 | Epidemiology of Hepatitis E in Pregnant Women and Children in Iran: A General Overview |
| Q40507459 | Epidemiology of Hepatitis E. |
| Q38076254 | Epidemiology of mammalian hepatitis E virus infection |
| Q35086897 | Epidemiology of zoonotic hepatitis E: a community-based surveillance study in a rural population in China |
| Q47132009 | Escherichia coli-derived virus-like particles in vaccine development |
| Q57000371 | Estimating the burden of maternal and neonatal deaths associated with jaundice in Bangladesh: possible role of hepatitis E infection |
| Q89965385 | Expression, Purification and Characterization of the Hepatitis E Virus Like-Particles in the Pichia pastoris |
| Q38792960 | Extra-hepatic replication and infection of hepatitis E virus in neuronal-derived cells |
| Q45361732 | Fatal course of an autochthonous hepatitis E virus infection in a patient with leukemia in Germany |
| Q34399964 | Fatal hepatitis E viral infection in pregnant women in Ghana: a case series |
| Q37978428 | Fatal outbreaks of jaundice in pregnancy and the epidemic history of hepatitis E. |
| Q37573028 | Fetal and neonatal health consequences of vertically transmitted hepatitis E virus infection |
| Q56656389 | First HEV vaccine approved |
| Q35078635 | From barnyard to food table: the omnipresence of hepatitis E virus and risk for zoonotic infection and food safety |
| Q87957089 | Functional ferritin nanoparticles for biomedical applications |
| Q38870888 | Generation of virus-like particles for emerging epizootic haemorrhagic disease virus: Towards the development of safe vaccine candidates. |
| Q44690707 | Genetic susceptibility to hepatitis E viral infection: An enigmatic virus gives up a secret |
| Q40334315 | Genotype-Specific Evolution of Hepatitis E Virus |
| Q47550305 | Guillain-Barre syndrome caused by hepatitis E infection: case report and literature review |
| Q92781216 | HEV study protocol : design of a cluster-randomised, blinded trial to assess the safety, immunogenicity and effectiveness of the hepatitis E vaccine HEV 239 (Hecolin) in women of childbearing age in rural Bangladesh |
| Q37727724 | Harnessing Nanoparticles for Immunomodulation and Vaccines |
| Q38520338 | Health disparities in liver disease in sub-Saharan Africa. |
| Q40225311 | Health economic evaluation of immunization strategies of hepatitis E vaccine for elderly population. |
| Q35501190 | Hepatitis C virus: Is it time to say goodbye yet? Perspectives and challenges for the next decade |
| Q56656388 | Hepatitis E |
| Q56769659 | Hepatitis E |
| Q26741395 | Hepatitis E Pathogenesis |
| Q56915346 | Hepatitis E Virus |
| Q92376567 | Hepatitis E Virus Drug Development |
| Q90228510 | Hepatitis E Virus Entry |
| Q54257512 | Hepatitis E Virus Genome Structure and Replication Strategy. |
| Q92113919 | Hepatitis E Virus Infections Among Human Immunodeficiency Virus-Positive Individuals During an Outbreak of Acute Hepatitis A in Taiwan |
| Q36480572 | Hepatitis E Virus Seroprevalence Among Blood Donors in Bushehr, South of Iran. |
| Q99712936 | Hepatitis E Virus and rheumatic diseases: what do rheumatologists need to know? |
| Q37535772 | Hepatitis E Virus in 3 Types of Laboratory Animals, China, 2012-2015 |
| Q40678496 | Hepatitis E Virus in Surface Water, Sediments, and Pork Products Marketed in Southern Brazil. |
| Q92802072 | Hepatitis E as a cause of adult hospitalization in Bangladesh: Results from an acute jaundice surveillance study in six tertiary hospitals, 2014-2017 |
| Q27002938 | Hepatitis E in Germany--an under-reported infectious disease |
| Q37030207 | Hepatitis E in Israel: A nation-wide retrospective study |
| Q38720607 | Hepatitis E in Transplantation. |
| Q38291885 | Hepatitis E in developed countries: current status and future perspectives |
| Q30238550 | Hepatitis E infection among Ghanaians: a systematic review |
| Q35849810 | Hepatitis E infection during pregnancy |
| Q40960395 | Hepatitis E infections in rheumatology. A previously underestimated infectious disease? |
| Q43088408 | Hepatitis E outbreak, Dadaab refugee camp, Kenya, 2012. |
| Q92172574 | Hepatitis E should be considered a neglected tropical disease |
| Q53354672 | Hepatitis E vaccine debuts. |
| Q54334450 | Hepatitis E vaccine development: a 14 year odyssey. |
| Q41089524 | Hepatitis E vaccine immunization for rabbits to prevent animal HEV infection and zoonotic transmission |
| Q92230479 | Hepatitis E vaccine in China: Public health professional perspectives on vaccine promotion and strategies for control |
| Q43320118 | Hepatitis E vaccine: not a moment too soon |
| Q64100657 | Hepatitis E virus (HEV)-The Future |
| Q40118705 | Hepatitis E virus ORF 1 induces proliferative and functional T-cell responses in patients with ongoing and resolved hepatitis E. |
| Q26751267 | Hepatitis E virus as an emerging zoonotic pathogen |
| Q36678270 | Hepatitis E virus capsid protein assembles in 4M urea in the presence of salts |
| Q38917141 | Hepatitis E virus enters liver cells through a dynamin-2, clathrin and membrane cholesterol-dependent pathway |
| Q42672108 | Hepatitis E virus genotype 4 isolated from a patient with liver failure: full-length sequence analysis showing potential determinants of virus pathogenesis |
| Q37098206 | Hepatitis E virus in developed countries: one of the most successful zoonotic viral diseases in human history? |
| Q37544935 | Hepatitis E virus infection |
| Q56752720 | Hepatitis E virus infection |
| Q96299192 | Hepatitis E virus infection during pregnancy |
| Q26777044 | Hepatitis E virus infection: Epidemiology and treatment implications |
| Q37473517 | Hepatitis E virus infections in humans and animals |
| Q52699055 | Hepatitis E virus replication and interferon responses in human placental cells. |
| Q39354799 | Hepatitis E virus seroprevalence among farmers, veterinarians and control subjects in Jilin province, Shandong province and Inner Mongolia Autonomous Region, China |
| Q37375936 | Hepatitis E virus: Current epidemiology and vaccine |
| Q45324469 | Hepatitis E virus: advances and challenges |
| Q27011308 | Hepatitis E virus: do locally acquired infections in Australia necessitate laboratory testing in acute hepatitis patients with no overseas travel history? |
| Q38014371 | Hepatitis E virus: neutralizing sites, diagnosis, and protective immunity |
| Q26852254 | Hepatitis E, a vaccine-preventable cause of maternal deaths |
| Q33629182 | Hepatitis E-associated encephalopathy in a renal transplant recipient |
| Q92144891 | Hepatitis E-related adverse pregnancy outcomes and their prevention by hepatitis E vaccine in a rabbit model |
| Q47156053 | Hepatitis E: A Literature Review |
| Q38379216 | Hepatitis E: A disease of reemerging importance |
| Q28079743 | Hepatitis E: Discovery, global impact, control and cure |
| Q35635630 | Hepatitis E: Epidemiology and prevention |
| Q36254854 | Hepatitis E: Risk and Prevention |
| Q55038767 | Hepatitis E: Still Waters Run Deep. |
| Q57071509 | Hepatitis E: The endemic perspective |
| Q54254955 | Hepatitis E: Update on Prevention and Control. |
| Q38582155 | Hepatitis E: an emerging global disease - from discovery towards control and cure |
| Q35049128 | Hepatitis E: an old infection with new implications. |
| Q64082955 | Hepatitis E: an underestimated emerging threat |
| Q50524547 | Hepatitis E: are psychiatric patients on special risk? |
| Q38137898 | Hepatitis E: current status. |
| Q38839954 | Hepatitis E: latest developments in knowledge. |
| Q38066540 | Hepatitis E: source and route of infection, clinical manifestations and new developments |
| Q30234939 | Hepatitis E: the current state of play. |
| Q26765433 | Hepatitis Vaccines |
| Q53156790 | Hepatitis a and e infection in international travellers. |
| Q37613188 | Hepatitis e and acute liver failure in pregnancy. |
| Q35072039 | Hepatitis e vaccine to prevent morbidity and mortality during epidemics |
| Q38371529 | Hepatitis e: epidemiology and natural history |
| Q55003727 | Hepatitis in a renal transplant patient-beyond the usual. |
| Q44923235 | Hepatitis: Hepatitis E vaccination--is HEV 239 the breakthrough? |
| Q33773545 | High Hepatitis E Seroprevalence Among Displaced Persons in South Sudan |
| Q37544940 | Host immune status and response to hepatitis E virus infection. |
| Q40191458 | Identification of Strategic Residues at the Interface of Antigen-Antibody Interactions by In Silico Mutagenesis |
| Q47561286 | Immunity against hepatitis E virus infection: Implications for therapy and vaccine development |
| Q52659699 | Immunization against Hepatitis E. |
| Q40507436 | Immunobiology and Host Response to HEV. |
| Q37694885 | Immunogenicity and safety of hepatitis E vaccine in healthy hepatitis B surface antigen positive adults |
| Q58096862 | Impfung bei Virushepatitis |
| Q45354410 | Increased risk of hepatitis E virus infection in schizophrenia |
| Q42253296 | Indigenous hepatitis E in England and wales from 2003 to 2012: evidence of an emerging novel phylotype of viruses. |
| Q37221544 | Influence of chronic HBV infection on superimposed acute hepatitis E. |
| Q38096721 | Intervention strategies for emerging viruses: use of antivirals |
| Q39222506 | Investigation of hepatitis E outbreak among refugees - Upper Nile, South Sudan, 2012-2013. |
| Q39025545 | Investigation of underlying comorbidities as risk factors for symptomatic human hepatitis E virus infection |
| Q38547282 | Is hepatitis E virus an emerging problem in industrialized countries? |
| Q47556196 | Knowledge gaps and research priorities in the prevention and control of hepatitis E virus infection. |
| Q40507410 | Laboratory Diagnosis of HEV Infection |
| Q27013018 | Lessons learned from successful human vaccines: Delineating key epitopes by dissecting the capsid proteins |
| Q59349514 | Life cycle and morphogenesis of the hepatitis E virus |
| Q37334112 | Liver diseases in pregnancy: diseases not unique to pregnancy |
| Q64108455 | Long-term Antibody Persistence After Hepatitis E Virus Infection and Vaccination in Dongtai, China |
| Q55505914 | Long-term HEV carriers without antibody seroconversion among eligible immunocompetent blood donors. |
| Q38212391 | Making the case for the development of a vaccination against hepatitis E virus. |
| Q37534616 | Management of hepatitis E virus (HEV) zoonotic transmission: protection of rabbits against HEV challenge following immunization with HEV 239 vaccine |
| Q43326979 | Maternal transfer of antibodies to the offspring after mice immunization with insect larvae-derived recombinant hepatitis E virus ORF-2 proteins. |
| Q35905989 | Maternal-Fetal Hepatitis E Transmission: Is It Underestimated? |
| Q40781273 | Modeling the long-term antibody response of a hepatitis E vaccine. |
| Q28066101 | Molecular Biology and Infection of Hepatitis E Virus |
| Q34166393 | Molecular virology of hepatitis E virus |
| Q35066861 | Mystery of hepatitis e virus: recent advances in its diagnosis and management |
| Q39076542 | Nanocaged platforms: modification, drug delivery and nanotoxicity. Opening synthetic cages to release the tiger |
| Q34152290 | Naturally occurring animal models of human hepatitis E virus infection |
| Q85016222 | Neglected hepatitis E and typhoid vaccines |
| Q51005441 | Nepali earthquakes and the risk of an epidemic of hepatitis E. |
| Q54229856 | Nonhuman Primate Models of Hepatitis A Virus and Hepatitis E Virus Infections. |
| Q33744177 | Older men with unexplained hepatitis |
| Q33800452 | Open reading frame 3 of genotype 1 hepatitis E virus inhibits nuclear factor-κappa B signaling induced by tumor necrosis factor-α in human A549 lung epithelial cells |
| Q36779845 | Pathobiology of hepatitis E: lessons learned from primate models |
| Q41847633 | Peek-a-boo: membrane hijacking and the pathogenesis of viral hepatitis |
| Q41951450 | Post-earthquake Nepal: the way forward |
| Q48504993 | Pregnancy and infection: using disease pathogenesis to inform vaccine strategy |
| Q64359484 | Pregnant women & vaccines against emerging epidemic threats: Ethics guidance for preparedness, research, and response |
| Q35823844 | Prevalence of Hepatitis E Virus among Adults in South-West of Iran |
| Q39804868 | Prevention of hepatitis E: another step forward |
| Q35019463 | Prior infection of pigs with a genotype 3 swine hepatitis E virus (HEV) protects against subsequent challenges with homologous and heterologous genotypes 3 and 4 human HEV |
| Q40507392 | Prophylactic Hepatitis E Vaccine |
| Q92808828 | Prophylactic Hepatitis E Vaccines: Antigenic Analysis and Serological Evaluation |
| Q38699244 | Prophylaxis against hepatitis E: at risk populations and human vaccines. |
| Q98245645 | Quantitative evaluation of protective antibody response induced by hepatitis E vaccine in humans |
| Q45350876 | Rabbit and human hepatitis E virus strains belong to a single serotype |
| Q56909142 | Reactive and pre-emptive vaccination strategies to control hepatitis E infection in emergency and refugee settings: A modelling study |
| Q40477519 | Real-time stability of a hepatitis E vaccine (Hecolin®) demonstrated with potency assays and multifaceted physicochemical methods. |
| Q38075857 | Recent advances in molecular medicine techniques for the diagnosis, prevention, and control of infectious diseases |
| Q51782806 | Recombinant Zika virus envelope protein elicited protective immunity against Zika virus in immunocompetent mice. |
| Q38114733 | Review of hepatitis B surveillance in China: improving information to frame future directions in prevention and control |
| Q38268414 | Risk factors for hepatitis E virus infection and disease. |
| Q42212470 | Robust manufacturing and comprehensive characterization of recombinant hepatitis E virus-like particles in Hecolin(®). |
| Q91524746 | Safety and immunogenicity of hepatitis E vaccine in elderly people older than 65 years |
| Q34290684 | Safety of an Escherichia coli-expressed bivalent human papillomavirus (types 16 and 18) L1 virus-like particle vaccine: an open-label phase I clinical trial. |
| Q26767097 | Self-assembling protein nanoparticles in the design of vaccines |
| Q34806688 | Seroprevalence of Hepatitis E Virus Infection among Swine Farmers and the General Population in Rural Taiwan |
| Q34512043 | Seroprevalence of hepatitis E virus in Hong Kong, 2008-2009. |
| Q42999395 | Should we screen blood products for hepatitis E virus RNA ? |
| Q38780261 | Specific memory B cell response and participation of CD4+ central and effector memory T cells in mice immunized with liposome encapsulated recombinant NE protein based Hepatitis E vaccine candidate |
| Q27666250 | Structural basis for the neutralization and genotype specificity of hepatitis E virus |
| Q35578943 | Structural basis for the neutralization of hepatitis E virus by a cross-genotype antibody |
| Q37858159 | Structure of hepatitis E viral particle |
| Q33812653 | Subviral particle as vaccine and vaccine platform |
| Q40417153 | Surveillance at Private Laboratories Identifies Small Outbreaks of Hepatitis E in Urban Bangladesh. |
| Q42278855 | Susceptibility of laboratory rats against genotypes 1, 3, 4, and rat hepatitis E viruses |
| Q35558184 | Swine is a possible source of hepatitis E virus infection by comparative study of hepatitis A and E seroprevalence in Thailand |
| Q64375183 | T Lymphocytes as Measurable Targets of Protection and Vaccination Against Viral Disorders |
| Q92829439 | Targeted hepatitis E vaccination for women of childbearing age is cost-effective in China |
| Q91714520 | The Clinical Perspective on Hepatitis E |
| Q40059581 | The Enigma of Hepatitis E Virus |
| Q48449074 | The biopharmaceutical industry in China: history and future perspectives |
| Q34464464 | The development of a recombinant hepatitis E vaccine HEV 239. |
| Q57241777 | The emergence of hepatitis E virus in Europe |
| Q37960564 | The epidemiology of hepatitis E virus infections in developed countries and among immunocompromised patients. |
| Q30248393 | The global burden of hepatitis E outbreaks: a systematic review. |
| Q45361424 | The global burden of hepatitis E virus genotypes 1 and 2 in 2005. |
| Q34533596 | The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013 |
| Q35092694 | The prevalence of hepatitis E virus infections among swine, swine farmers and the general population in Guangdong Province, China |
| Q28084036 | Therapeutic targets for the treatment of hepatitis E virus infection |
| Q40555108 | Time course of hepatitis E-specific antibodies in adults |
| Q28730718 | Toolbox for non-intrusive structural and functional analysis of recombinant VLP based vaccines: a case study with hepatitis B vaccine |
| Q37881208 | Toward the development of a hepatitis E vaccine |
| Q52358472 | Transmission and Epidemiology of Hepatitis E Virus Genotype 3 and 4 Infections. |
| Q33734018 | Transmission, diagnosis, and management of hepatitis E: an update |
| Q38972857 | Types, frequencies, and burden of nonspecific adverse events of drugs: analysis of randomized placebo-controlled clinical trials. |
| Q51784137 | Vaccine Development against Zoonotic Hepatitis E Virus: Open Questions and Remaining Challenges. |
| Q42272319 | Viral hepatitis in solid organ transplantation |
| Q37130825 | Viral hepatitis vaccination during pregnancy |
| Q40806990 | Virology, serology, and demography of hepatitis E viremic blood donors in South East England. |
| Q38088523 | Virus-like particles: the future of microbial factories and cell-free systems as platforms for vaccine development |
| Q64900266 | Why all blood donations should be tested for hepatitis E virus (HEV). |
| Q36825509 | World Health Organization International Standard to harmonize assays for detection of hepatitis E virus RNA. |
| Q64127662 | World Hepatitis Day: a new era for hepatitis control |
| Q35072079 | World health organization approaches to evaluating the potential use and quality of hepatitis e vaccine. |
| Q38353549 | Xenotransplantation and Hepatitis E virus |
| Q28070204 | Zoonotic Hepatitis E Virus: Classification, Animal Reservoirs and Transmission Routes |
| Q83459651 | [Prevention of virus hepatitis A to E] |
| Q45825862 | Infection par le virus de l’hépatite E durant la grossesse |
Search more.